Role of CD154 in cancer pathogenesis and immunotherapy

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• CD154 (Cluster of Differentiation 154) is a co-stimulatory molecule initially recognized for its role in T cell-dependent humoral responses through CD40 interaction.
• CD154 also participates in cell-mediated immunity and inflammation via CD40 and integrin family receptors, contributing to autoimmune diseases.
• The multifaceted roles of CD154 in both cancer development and immune surveillance are increasingly recognized.

Purpose of the Study:

• To provide a comprehensive overview of CD154's involvement in cancer pathogenesis.
• To explore CD154's potential as an immunotherapeutic target in cancer treatment.
• To review in vitro, in vivo, and clinical studies investigating the CD154 system in cancer.

Main Methods:

• Literature review of existing studies on CD154 in cancer.
• Analysis of CD154's role in tumor proliferation, apoptosis resistance, and invasiveness.
• Examination of CD154's immuno-regulatory functions against cancer, including antigen-presenting cell stimulation and immune microenvironment modulation.

Main Results:

• CD154 can act as an etiological factor in tumors, promoting malignant cell proliferation, survival, and invasiveness.
• CD154 exhibits immuno-regulatory functions against cancer, enhancing anti-tumor immunity by activating effector cells and increasing tumor immunogenicity.
• Clinical studies show progress in leveraging CD154's functions for cancer therapy.

Conclusions:

• The CD154 system plays a complex role in cancer, acting as both a potential driver of disease and a target for immunotherapy.
• Further understanding of CD154's dual functions can lead to novel strategies for cancer prevention and treatment.
• Targeting the CD154 pathway holds promise for improving cancer management and patient outcomes.